J. Goldman & Co’s Biogen BIIB Stock Holding History

J. Goldman & Co’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-56,921	Closed	-$14M	–	355
2023 Q3	$14.6M	Buy	+56,921	New	+$15.2M	0.51%	61
2023 Q2	–	Sell	-40,636	Closed	-$11.3M	–	385
2023 Q1	$11.3M	Buy	40,636 +28,426	+233%	+$7.87M	0.46%	69
2022 Q4	$3.38M	Buy	12,210 +4,131	+51%	+$1.17M	0.17%	135
2022 Q3	$2.16M	Sell	8,079 -8,736	-52%	-$1.86M	0.1%	202
2022 Q2	$3.43M	Buy	+16,815	New	+$3.44M	0.17%	147
2021 Q1	–	Sell	-3,657	Closed	-$895K	–	438
2020 Q4	$895K	Buy	+3,657	New	+$943K	0.05%	244

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

J. Goldman & Co's BIIB Position: Q4 2023 in Review

J. Goldman & Co sold out of Biogen (BIIB) in Q4 2023, closing a stake of 56,921 shares — an estimated $14M sold.

J. Goldman & Co first reported a position in BIIB in Q4 2020 and held it in 6 quarters. The position peaked at $14.6M in Q3 2023. 1,003 funds tracked by Wall St. Rank hold BIIB as of Q4 2023.

J. Goldman & Co reported no remaining Biogen position as of Q4 2023 after selling out during the quarter.
J. Goldman & Co sold 56,921 Biogen shares in Q4 2023, an estimated $14M.
J. Goldman & Co first reported a position in Biogen in Q4 2020 and held it in 6 quarters.
J. Goldman & Co's Biogen position peaked at $14.6M in Q3 2023.
1,003 funds tracked by Wall St. Rank held Biogen as of Q4 2023.

Based on J. Goldman & Co's 13F filing for Q4 2023, filed 14 Feb 2024.